Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

842 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium. Bradley CA, et al. Among authors: tabernero j. Nat Rev Clin Oncol. 2017 Sep;14(9):562-576. doi: 10.1038/nrclinonc.2017.40. Epub 2017 Apr 4. Nat Rev Clin Oncol. 2017. PMID: 28374784 Review.
Novel targets in gastric and esophageal cancer.
Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J. Valverde CM, et al. Among authors: tabernero j. Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38. doi: 10.1016/j.critrevonc.2006.02.001. Epub 2006 Jul 10. Crit Rev Oncol Hematol. 2006. PMID: 16829119
The role of salvage treatment in advanced colorectal cancer.
Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Crit Rev Oncol Hematol. 2009 Jul;71(1):53-61. doi: 10.1016/j.critrevonc.2008.09.006. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977669 Review.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F. Tabernero J, et al. J Clin Oncol. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100964 Clinical Trial.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. De Roock W, et al. Among authors: tabernero j. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Di Nicolantonio F, et al. Among authors: tabernero j. J Clin Invest. 2010 Aug;120(8):2858-66. doi: 10.1172/JCI37539. Epub 2010 Jul 26. J Clin Invest. 2010. PMID: 20664172 Free PMC article.
842 results